Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hellmann

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Physical Review Letters|January 15, 2011
Ultrafast melting of a charge-density wave in the Mott insulator 1T-TaS2S Hellmann, M Beye, C Sohrt, et al.
AIDS (London, England)|October 9, 2002
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysisRichard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
AIDS (London, England)|February 19, 2005
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575Richard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
The Journal of Infectious Diseases|June 25, 2004
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infectionJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
The Journal of Infectious Diseases|March 28, 2003
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka, Guido Ferrari, Victoria E Gryszowka, et al.
The Journal of Infectious Diseases|January 25, 2002
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapySteven G Deeks, Rebecca Hoh, Robert M Grant, et al.
AIDS (London, England)|April 24, 2001
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitorsC A Kemper, M D Witt, P H Keiser, et al.
The New England Journal of Medicine|August 9, 2002
Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little, Sarah Holte, Jean-Pierre Routy, et al.
Journal of Virology|October 24, 2000
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sitesA J Brown, H M Precious, J M Whitcomb, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Physical Review Letters|January 15, 2011
Ultrafast melting of a charge-density wave in the Mott insulator 1T-TaS2S Hellmann, M Beye, C Sohrt, et al.
AIDS (London, England)|October 9, 2002
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysisRichard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
AIDS (London, England)|February 19, 2005
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575Richard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
The Journal of Infectious Diseases|June 25, 2004
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infectionJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
The Journal of Infectious Diseases|March 28, 2003
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka, Guido Ferrari, Victoria E Gryszowka, et al.
The Journal of Infectious Diseases|January 25, 2002
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapySteven G Deeks, Rebecca Hoh, Robert M Grant, et al.
AIDS (London, England)|April 24, 2001
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitorsC A Kemper, M D Witt, P H Keiser, et al.
The New England Journal of Medicine|August 9, 2002
Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little, Sarah Holte, Jean-Pierre Routy, et al.
Journal of Virology|October 24, 2000
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sitesA J Brown, H M Precious, J M Whitcomb, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
Pageof 6